Comparative Pharmacology
Head-to-head clinical analysis: GILDESS FE 1 5 30 versus PORTIA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILDESS FE 1 5 30 versus PORTIA 21.
GILDESS FE 1.5/30 vs PORTIA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol (estrogen) and levonorgestrel (progestin) suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Ethinyl estradiol: terminal elimination half-life approximately 13-27 hours (mean ~17 hours); clinical context: supports daily dosing with steady state achieved in ~1 week. Gestodene: terminal elimination half-life approximately 12-15 hours; clinical context: allows for maintaining stable serum concentrations with once-daily dosing.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Ethinyl estradiol (EE) is primarily excreted in urine (40-45%) and feces (40-45%) as glucuronide and sulfate conjugates; less than 8% is excreted unchanged. Gestodene is extensively metabolized; its metabolites are excreted in urine (50-60%) and feces (30-40%), with less than 1% unchanged.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Category C
Category C
Oral Contraceptive
Oral Contraceptive